

EVALUATION ORIGINAL

Test Method	Specimen	Your Result	Intended Response	Your Grade
ABO Group	ETM1-01R	ADDL TESTING/ SAMPL REQD	74.7% J	See Note [26]
ABO Subgroup	ETM1-01R	GROUP A1	83.1% - did not perform J	See Note [26]
Rh Type	ETM1-01R	RH POSITIVE	98.8% J	See Note [26]
Antibody Detection	ETM1-01S	ANTIBODY DETECTED	98.9% J	See Note [26]
Antibody ID	ETM1-01S	Anti-Fya	95.5% J	See Note [26]
Anti-C	ETM1-01R	POSITIVE	100% J	See Note [26]
Anti-E	ETM1-01R	NEGATIVE	98.3% J	See Note [26]
Anti-c	ETM1-01R	POSITIVE	98.3% J	See Note [26]
Anti-e	ETM1-01R	POSITIVE	100% J	See Note [26]
Other Antigen 1	ETM1-01R	Anti-Fya NEGATIVE	98.3% M?	See Note [26]
DAT Poly	ETM1-01R	POSITIVE	overall	See Note [26]
DAT IgG	ETM1-01R	POSITIVE	68.3% 95.8% Gel J	See Note [26]
DAT C3b/ C3d	ETM1-01R	NEGATIVE	70.5% 90.3% Gel J 63.3% 81% Tube J	See Note [26]

**EVALUATION
ORIGINAL**

ETME-A 2021 Expanded Trans Med Exercises

Test Method	Specimen	Your Result	Intended Response	Your Grade
DAT C3	ETM1-01R	NEGATIVE	31.5% 67.1% Not Tested Tuberc 100%	See Note [26]
Equate antibody ID	ETM1-01R	Anti-A 27.1% <i>J</i>	Not indicated 60% <i>J</i>	See Note [26]
Dry Lab Challenge	ETM1-03	TA-GVHD ASSOC PANCYTOP <i>J</i> 93.2% PATHOGEN REDUCTION 72.7% SEVERE COMBINED SCID. 25.1% ACUTE LEUKEMIA PT BONE 26.6% CROSSMATCH-COMPATIBLE PLT 11.2% PATIENT WITH ANTI-PPIP 24.2% 15 GY / 25 GY / 50 GY 92% RBC / INCREASED EXTRAC 97.7%	<i>J</i>	See Note [26]